The outpatient management of febrile neutropenia in cancer patients

ONCOLOGY

Volumn 10, Issue 4, 1996, Pages 599-612

  Freifeld, Alison G ^b   Pizzo, Philip A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; GENTAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MEZLOCILLIN; OFLOXACIN; PEFLOXACIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

BACTERIAL INFECTION; CANCER PATIENT; FEVER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NEUTROPENIA; ORAL DRUG ADMINISTRATION; OUTPATIENT; PATIENT CARE; PSEUDOMONAS AERUGINOSA; QUALITY OF LIFE; REVIEW; RISK FACTOR; STAPHYLOCOCCUS AUREUS;

ADMINISTRATION, ORAL; AMBULATORY CARE; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; FEVER; GRAM-POSITIVE BACTERIA; HOME INFUSION THERAPY; HUMANS; NEOPLASMS; NEUTROPENIA; RECEPTORS, COLONY-STIMULATING FACTOR; RISK ASSESSMENT; RISK FACTORS;

EID: 0029948620     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Bodey G, Buckley M, Sathe Y, et al: Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64:328-340, 1966.
2. Pizzo P, Robichaud K, Wesley R, et al: Fever in the pediatric and young adults patient with cancer: a prospective study of 1001 episodes. Medicine 61:153-165, 1982.
3. Schimpff S, Young V, Greene W, et al: Origin of infection in acute nonlymphocytic leukemia: Significance of hospital acquisition of potential pathogens. Ann Intern Med 77:707-714, 1972.
4. Pizzo P: Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 328:1323-1332, 1993.
5. EORTC: Gram-positive bacteraemia in granulocytopenic cancer patients. Eur J Cancer 26:569-574, 1990.
6. EORTC: Three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with gram-negative bacteremia. J Infect Dis 137:14-20, 1978.
7. EORTC: Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. N Engl J Med 317:1692-1698, 1987
8. EORTC: Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med 119:584-593, 1993
9. Ramphal R, Bolger M, Oblon D, et al. Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime: A randomized prospective study. Antimicrob Agents Chemother 36:1062-1067, 1992
10. Gibson J, Johnson L, Snowdon L, et al: Single daily ceftriaxone and tobramycin in the empirical management of febrile neutropenic patients: A randomized trial. Int J Hematol 58:63-72, 1993.
11. Freifeld A, Walsh T, Marshall D, et al. Monotherapy for fever and neutropenia in cancer patients: A randomized comparison of ceftazidime versus imipenem. J Clin Oncol 13:165-176, 1995.
12. Rubin M, Hathorn J, Marshall D, et al: Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Ann Intern Med 108:30-35, 1988.
13. EORTC: Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. J Infect Dis 163:951-958, 1991.
14. Sanders J, Powe N, Moore R: Ceftazidime monotherapy for empiric treatment of febrile neutropenic patients: A metaanalysis. J Infect Dis 164:907-916, 1992.
15. Pizzo P, Hathorn J, Hiemenz J, et al: A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 315:552-558, 1986.
16. Rubin MM, Hathorn JW, Pizzo PA: Controversies in the management of febrile neutropenic cancer patients. Cancer Invest 6:167-184, 1988.
17. Talcott J, Finberg R, Mayer R. et al: The medical course of cancer patients with fever and neutropenia. Arch Intern Med 148:2561-2568, 1988.
18. Talcott J, Siegel R, Finberg R, et al: Risk assessment in cancer patients with fever and neutropenia: A prospective, two-center validation of a prediction rule. J Clin Oncol 10:316-322, 1992.
19. Talcott J, Whalen A. Clark J, et al: Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: A pilot study of 30 patients based on a validated prediction rule J Clin Oncol 12 107-114, 1994.
20. Brown RB: Outpatient parenteral therapy: Management of serious infections. Part I Medical, socioeconomic, and legal issues: Selecting the patient. Hosp Pract (office ed) 28(suppl 1): 11-15, 1993.
21. Rubenstein EB, Ralston KVI: Outpatient treatment of febrile neutropenic patients with cancer Eur J Cancer 31A:2-4, 1995.
22. Rubenstein E, Rolston K, Benjamin R. et al: Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer 71:3640-3646, 1993.
23. Martino P, Girmenia C, Raccah R. et al Single daily dose ceftriaxone plus amikacin treatment of febrile episodes in neutropenic patients attending day hospital for hematologic malignancies. Oncology 49:49-52, 1992.
24. Malik I: Randomized comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients. Lancet 339:1092-6, 1992.
25. Malik IA, Khan WA, Aziz Z, et al: Self administered antibiotic therapy for chemotherapy-induced, low-risk febrile neutropenia in patients with nonhematologic neoplasms. Clin Infect Dis 19:522-527, 1994
26. Malik I, Khan W, Karim M, et al: Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: Results of a prospective randomized trial. Am J Med 98:224-231, 1995
27. Rolston K, Rubenstein EB, Elting LS. et al: Ambulatory management of febrile episodes in low-risk neutropenic patients-an acceptable alternative to hospital based therapy (abstract P-21). in Program Proceedings and Abstracts of the 6th international Symposium Supportive Care in Cancer, 1994.
28. Pizzo P, Robichaud K, Gill F, et al : Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 72:101-111, 1982.
29. Buchanan G: Approach to the treatment of the febrile cancer patient with low-risk neutropenia. Hematology/Oncology Clinics of North America: Infectious Complications in the Immunocompromised Host II 7:919-935, 1993.
30. Bash R, Katz J, Cash J, et al: Safety and cost effectiveness of early hospital discharge of lower risk children with cancer admitted for fever and neutropenia Cancer 74:189-196, 1994.
31. Jones OR, Konsler GK, RP Dunaway, et al. Risk factors for recurrent fever after the discontinuation of empiric antibiotic therapy for fever and neutropenia in pediatric patients with a malignancy or hematologic condition. J Ped 124:703-708, 1994.